Study of Advanced Eu(II)-Based Contrast Agents for Ultra-High Field Magnetic Reso
Study of Advanced Eu(II)-Based Contrast Agents for Ultra-High Field Magnetic Reso
批准号:
9059260
负责人:
MATTHEW J ALLEN
金额:
$5.12万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-05-01 至 2017-04-30
关键词:
AirAntioxidantsAreaBiodistributionBiological AssayBrainBrain imagingChargeChemical StructureChemicalsClinicalClinical ResearchComplexContrast MediaCoupledDevelopmentDiagnosisDiagnosticDiagnostic ImagingDiseaseDrug FormulationsDrug-sensitiveEarly DiagnosisFoundationsFutureGoalsHealthHeart DiseasesHemoglobinHousingImageIn VitroInvestmentsKineticsLeadLigandsMagnetic Resonance ImagingMalignant NeoplasmsMaximum Tolerated DoseMeasurementMedicineMissionModificationMolecularMonitorOutcomePatientsPatternPropertyPublic HealthRelative (related person)ResearchResearch ProposalsResolutionRheumatoid ArthritisScanningSeriesStrokeStructure-Activity RelationshipTherapeuticTimeToxic effectTranslatingTranslationsTraumatic Brain InjuryUnited States National Institutes of Healthbasecontrast enhanceddisease diagnosiseffective therapyfunctional grouphuman diseaseimprovedin vivoin vivo imaginginnovationmagnetic fieldmeetingsoxidationplanetary Atmospherepre-clinical researchsuccesstool
中文摘要
描述(由申请人提供):超高场强(e7t)磁共振成像(MRI)非常需要正性造影剂,以提高临床前和临床研究中对疾病状态的空间分辨率和敏感性。我们的长期目标是开发用于超高场强MRI的正性造影剂,通过专注于最有前途的研究领域EuII复合物来填补诊断医学的这一空白。本申请的总体目标是通过最大化稳定性、优化成像特性和评估毒性,为我们新的euii基配合物转化为有用的造影剂奠定必要的基础。正如我们最近所证明的那样,支持拟议研究的基本原理是,EuII可以通过配体修饰和抗氧化剂配方来稳定抗氧化并在体内无毒。该提案的预期结果是建立euii基配合物,用作超高场强MRI的造影剂。预计这一结果将对NIH在人类疾病诊断方面的使命产生积极影响。我们计划通过追求三个具体目标来实现提案的目标:(1)化学增强我们的含euii配合物的稳定性和成像相关参数;(2)表征含EuII配合物的毒性;(3)表征含euii复合物的体内成像特性。新的基于euii的探针将具有重要意义,因为它们有望在比目前在临床领域获得的诊断图像更短的时间内以更高的分辨率在超高场强下获得诊断图像
英文摘要
DESCRIPTION (provided by applicant): There is a great need for positive contrast agents for ultra-high field strength (e7 T) magnetic resonance imaging (MRI) to enable increased spatial resolution and sensitivity to disease states in both preclinical and clinical research. Our long-term goal is to develop positive contrast agents for ultra-high field strength MRI to fill this voi in diagnostic medicine by focusing on EuII complexes that are among the most promising areas of study. The overall objective of this application is to establish the groundwork necessary for translation of our new EuII-based complexes into useful contrast agents by maximizing stability, optimizing imaging properties, and evaluating toxicity. The rationale that underpins the proposed research is that EuII can be stabilized against oxidation and rendered non-toxic in vivo through ligand modification and formulation with antioxidants as we have recently demonstrated. The expected outcome of this proposal is the establishment of EuII-based complexes for use as contrast agents in ultra-high field strength MRI. This outcome is expected to have a positive impact by contributing to the NIH's mission in the diagnosis of human diseases. We plan to achieve the objective of the proposal by pursuing three specific aims: (1) to chemically enhance the stabilities and imaging-relevant parameters of our EuII-containing complexes; (2) to characterize the toxicity of our EuII- containing complexes; and (3) to characterize the in vivo imaging properties of our EuII-containing complexes. The new EuII-based probes will be significant because they are expected to enable diagnostic images to be acquired at ultra-high field strengths with higher resolution in less time than those currently acquired at clinical field
strengths. Furthermore, because ultra-high field strengths are commonplace in NIH-supported preclinical research, this proposal is expected to maximize returns in the many other investments of the NIH related to MRI.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MARC at Wayne State University
-
批准号:10408118
-
项目类别:
-
资助金额:$39.67万
-
财政年份:2021
-
负责人:MATTHEW J ALLEN
-
依托单位:
MARC at Wayne State University
-
批准号:10620738
-
项目类别:
-
资助金额:$40.13万
-
财政年份:2021
-
负责人:MATTHEW J ALLEN
-
依托单位:
Library Synthesis and Screening of Eu(II)-Based Contrast Agents
-
批准号:10093042
-
项目类别:
-
资助金额:$31.56万
-
财政年份:2019
-
负责人:MATTHEW J ALLEN
-
依托单位:
Library Synthesis and Screening of Eu(II)-Based Contrast Agents
-
批准号:10377906
-
项目类别:
-
资助金额:$32.01万
-
财政年份:2019
-
负责人:MATTHEW J ALLEN
-
依托单位:
Library Synthesis and Screening of Eu(II)-Based Contrast Agents
-
批准号:10330634
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2019
-
负责人:MATTHEW J ALLEN
-
依托单位:
Intratumoral imaging of hypoxia using 1H- and 19F-MRI with redox-responsive Eu-based contrast agents
-
批准号:10239104
-
项目类别:
-
资助金额:$65.61万
-
财政年份:2018
-
负责人:MATTHEW J ALLEN
-
依托单位:
Study of Advanced Eu(II)-Based Contrast Agents for Ultra-High Field Magnetic Reso
-
批准号:8628271
-
项目类别:
-
资助金额:$32.54万
-
财政年份:2014
-
负责人:MATTHEW J ALLEN
-
依托单位:
Study of Advanced Eu(II)-Based Contrast Agents for Ultra-High Field Magnetic Reso
-
批准号:9043062
-
项目类别:
-
资助金额:$33.6万
-
财政年份:2014
-
负责人:MATTHEW J ALLEN
-
依托单位:
Study of Advanced Eu(II)-Based Contrast Agents for Ultra-High Field Magnetic Reso
-
批准号:8806558
-
项目类别:
-
资助金额:$31.76万
-
财政年份:2014
-
负责人:MATTHEW J ALLEN
-
依托单位:
Increasing the Utility of Contrast Agents for MRI
-
批准号:7753605
-
项目类别:
-
资助金额:$24.75万
-
财政年份:2008
-
负责人:MATTHEW J ALLEN
-
依托单位:
Increasing the Utility of Contrast Agents for MRI
-
批准号:7515492
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2008
-
负责人:MATTHEW J ALLEN
-
依托单位:
Increasing the Utility of Contrast Agents for MRI
-
批准号:7541763
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2008
-
负责人:MATTHEW J ALLEN
-
依托单位:
Increasing the Utility of Contrast Agents for MRI
-
批准号:7223342
-
项目类别:
-
资助金额:$7.8万
-
财政年份:2006
-
负责人:MATTHEW J ALLEN
-
依托单位:
Multivalent Antibody Ligands for Clearance of Pathogens
-
批准号:6886737
-
项目类别:
-
资助金额:$4.4万
-
财政年份:2004
-
负责人:MATTHEW J ALLEN
-
依托单位:
Multivalent Antibody Ligands for Clearance of Pathogens
-
批准号:6793362
-
项目类别:
-
资助金额:$4.11万
-
财政年份:2004
-
负责人:MATTHEW J ALLEN
-
依托单位:
Multivalent Antibody Ligands for Clearance of Pathogens
-
批准号:7032333
-
项目类别:
-
资助金额:$3.49万
-
财政年份:2004
-
负责人:MATTHEW J ALLEN
-
依托单位:
海外基金